WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENCE® (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication for the treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older weighing at least 35 kg. The development of NUZOLVENCE was part of a private, not-for-profit collaboration.
The U.S. Food and Drug Administration has approved Innoviva's oral antibiotic for common sexually transmitted infection, offering patients a pill instead of the injection that is currently the only recommended treatment, the regulator said on Friday.
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced the publication of positive results from a pivotal Phase 3 trial evaluating its investigational single-dose, oral antibiotic zoliflodacin for the treatment of uncomplicated urogenital gonorrhea in The Lancet. The trial was sponsored and led by the Company's not-for-profit partner, the Global Antibiotic Research & Development Partnership (GARDP). “Gonorrhea c.
Boston Partners lifted its position in shares of Innoviva, Inc. (NASDAQ: INVA) by 40.6% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 875,084 shares of the biotechnology company's stock after acquiring an additional 252,534 shares during the quarter. Boston Partners owned approximately 1.39% of
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference in New York, NY on Tuesday, December 2, 2025 a.
Innoviva, Inc. (NASDAQ: INVA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company.
Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Innoviva, Inc. (NASDAQ: INVA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 78,903 shares of the biotechnology company's stock, valued at approximately $1,585,000. Connor
Innoviva (INVA) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.02 per share a year ago.
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2025, and highlighted select corporate progress and achievements. “Innoviva delivered strong t.
Innoviva (INVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
